Literature DB >> 2076730

Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.

G M Peterson1, R R Boyle, H W Francis, N W Oliver, J Paterson, R J von Witt, G R Taylor.   

Abstract

This study examined dosage prescribing patterns and steady-state oxipurinol plasma concentrations in 66 patients receiving chronic allopurinol therapy. Most patients (65%) were taking 300 mg allopurinol daily, although renal impairment was common. Using published guidelines, it was estimated that 35% of patients were receiving excessive dosages of allopurinol. Consequently, the plasma oxipurinol concentrations were often very high (mean (SD) was 156 (109) mumol.l-1). Accumulation of oxipurinol was inversely related to renal function. Plasma concentrations of oxipurinol and urate were not significantly related. However, most patients with oxipurinol concentrations of up to 100 mumol.l-1 had urate concentrations within the normal reference range.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076730     DOI: 10.1007/BF00315424

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Use and abuse of allopurinol.

Authors:  J S Cameron; H A Simmonds
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

3.  Plasma oxipurinol concentrations during allopurinol therapy.

Authors:  B T Emmerson; R B Gordon; M Cross; D B Thomson
Journal:  Br J Rheumatol       Date:  1987-12

4.  Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

Authors:  R O Day; J O Miners; D J Birkett; A Whitehead; D Naidoo; J Hayes; E Savdie
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

5.  Simultaneous determination of allopurinol, oxipurinol, hypoxanthine and xanthine in biological fluids by high-performance liquid chromatography.

Authors:  R Boulieu; C Bory; P Baltassat; C Gonnet
Journal:  J Chromatogr       Date:  1984-05-11

Review 6.  Clinical pharmacokinetics of allopurinol.

Authors:  G A Murrell; W G Rapeport
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

7.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

8.  The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.

Authors:  J Z Singer; S L Wallace
Journal:  Arthritis Rheum       Date:  1986-01
  8 in total
  10 in total

1.  The pharmacokinetics of oxypurinol in people with gout.

Authors:  Sophie L Stocker; Andrew J McLachlan; Radojka M Savic; Carl M Kirkpatrick; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  The role of non-P450 enzymes in drug oxidation.

Authors:  C Beedham
Journal:  Pharm World Sci       Date:  1997-12

3.  Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.

Authors:  K Turnheim; P Krivanek; R Oberbauer
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

4.  The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Authors:  Daniel F B Wright; Lisa K Stamp; Tony R Merriman; Murray L Barclay; Stephen B Duffull; Nicholas H G Holford
Journal:  Eur J Clin Pharmacol       Date:  2013-03-10       Impact factor: 2.953

5.  Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.

Authors:  W Löffler; R Landthaler; J X de Vries; I Walter-Sack; A Ittensohn; A Voss; N Zöllner
Journal:  Clin Investig       Date:  1994-12

Review 6.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Risks and benefits of drugs used in the management and prevention of gout.

Authors:  P G Conaghan; R O Day
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

8.  Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.

Authors:  Lisa K Stamp; Peter T Chapman; Murray Barclay; Anne Horne; Christopher Frampton; Tony R Merriman; Daniel F B Wright; Jill Drake; Nicola Dalbeth
Journal:  Clin Transl Sci       Date:  2019-09-03       Impact factor: 4.689

Review 9.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

Review 10.  Gout in the elderly. Clinical presentation and treatment.

Authors:  A G Fam
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 4.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.